The Power of Partnership to Address Antimicrobial Resistance

Antimicrobial Resistance (AMR) is a significant threat to global health and economic development. As the progression of AMR renders antibiotics less effective, common infections, such as wound infections, urinary tract infections, and pneumonia can increasingly be associated with severe complications and increased risk of death. AMR is a major driver of death globally, potentially accounting for more deaths than HIV/AIDS and malaria worldwide. The WHO estimates that the number of deaths due to AMR could rise to 10 million people a year by 2050 under the most alarming scenario if no action is taken. No one company or entity can tackle the issue alone. Partnerships and collaborations are critical to tackling the problem together.

In this discussion, moderated by Erika Satterwhite, Head of Global Policy at Viatris, a global healthcare company, with Melissa Gong Mitchell, Secretariat Lead for the AMR Industry Alliance, and Dr. Yehoda Martei, Assistant Professor of Medicine, and the Vice Chief of Diversity, Inclusion and Health Equity in the Division of Hematology-Oncology at the University of Pennsylvania, you will learn:

• The global impact of AMR, why it is growing at an accelerated rate and what happens if we don’t stop it

• The risk of AMR to cancer patients, who are more likely to be infected by multidrug-resistant bacteria • What can be done to combat AMR

• How the private sector, governments, patients, healthcare providers and other stakeholders can effectively come together to build common solutions

• Best practices for cross-disciplinary collaboration to address other global health issues

This webinar is sponsored by Viatris Inc.